22 Jul Mission Bio
Yan Zhang, Ph.D., CEO
Oct. 11 | 1:30pm | Oxford Biomedica Ballroom
San Francisco, CA
(Private)
In-person Presentation
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure, characterize, and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others. The company’s Tapestri Platform gives researchers around the globe the power to interrogate genotype and immunophenotype together in individual cells, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide.
